Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors

References

• Weycker D, Hatfield M, Grossman A, Hanau A, Lonshteyn A, Sharma A, Chandler D. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer 2019;19(1):151. doi:10.1186/s12885-019-5354-5.
   PubMedGoogle Scholar
• Wu Y, Aravind S, Ranganathan G, Martin A, L N. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther 2009;31:2416–2432. doi:10.1016/j.clinthera.2009.11.020.
   PubMed Web of Science ®Google Scholar
• Bussel J, Kulasekararaj A, Cooper N, Verma A, Steidl U, Semple JW, Will B. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Semin Hematol 2019;56(4):262–278. doi:10.1053/j.seminhematol.2019.09.001.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Yang S, Zeng W, Li M, Guan Z, Zhou L, Wang H, Liu Y, Gao Y, Qiu S, et al. A real-world observation of eltrombopag and recombinant human thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced thrombocytopenia. Front Oncol 2021;11:701539. doi:10.3389/fonc.2021.701539.
   PubMed Web of Science ®Google Scholar
• U.S. Department Of Health And Human Services. National Institutes of Health and National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 5.0. published on 2017 November 27.
   Google Scholar
• Stanworth S, Estcourt L, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Llewelyn C, Littlewood T, Soutar R, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013;368(19):1771–1780. doi:10.1056/NEJMoa1212772.
   PubMed Web of Science ®Google Scholar
• Tepler I, Elias L, Smith J, Hussein M, Rosen G, Chang AY, Moore JO, Gordon MS, Kuca B, Beach KJ, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87(9):3607–3614.
   PubMed Web of Science ®Google Scholar
• Alcaina S. Platelet transfusion: and update on challenges and outcomes. J Blood Med 2020;11:19–26. doi:10.2147/JBM.S234374.
   PubMed Web of Science ®Google Scholar
• Hume HA, Ddungu H, Angom R, Baluku H, Kajumbula H, Kyeyune-Byabazaire D, Orem J, Ramirez-Arcos S, Tobian AAR. Platelet transfusion therapy in sub‐Saharan Africa: bacterial contamination, recipient characteristics, and acute transfusion reactions. Transfusion 2016;56(8):1951–1959. doi:10.1111/trf.13594.
   PubMed Web of Science ®Google Scholar
• Xu Y, Song X, Du F, Zhao Q, Liu L, Ma Z, Lu S. A randomized controlled study of rhTPO and rhIL-11 for the prophylactic treatment of chemotherapy-induced thrombocytopenia in non-small cell lung cancer. J Cancer 2018;9(24):4718–4725. doi:10.7150/jca.26690.
   PubMed Web of Science ®Google Scholar
• Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol 2019;37(31):2892–2898. doi:10.1200/JCO.18.01931.
   PubMed Web of Science ®Google Scholar
• Winer E, Safran H, Karaszewska B, Richards DA, Hartner L, Forget F, Ramlau R, Kumar K, Mayer B, Johnson BM, et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med 2015;4(1):16–26. doi:10.1002/cam4.326.
   PubMed Web of Science ®Google Scholar
• Lee EJ, Seshadri M, Bussel JB. Clinical outcomes in eight patients with immune thrombocytopenia each treated with the three approved thrombopoietin receptor agonists. Am J Hematol 2021; 96(10):E373–E376. doi:10.1002/ajh.26277.
   PubMed Web of Science ®Google Scholar
• Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011; 51(6):842–856. doi:10.1177/0091270010375427.
   PubMed Web of Science ®Google Scholar
• Nomoto M, Pastino G, Rege B, Aluri J, Ferry J, Han DD. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev 2017;7:188–195. doi:10.1002/cpdd.349.
   PubMed Web of Science ®Google Scholar
• De Silva E, H K. Drug-induced thrombocytopenia: focus on platelet apoptosis. Chem Biol Interact 2018;284:1–11. doi:10.1016/j.cbi.2018.01.015.
   PubMed Web of Science ®Google Scholar
• Tralongo A, Antonuzzo A, Pronzato P, Sbrana A, Turrini M, Zoratto F, Danova M. Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian medical oncology association (AIOM). Tumori J 2020;106(4):273–280. doi:10.1177/0300891620927093.
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Levati G, Cassin R, Barcellini B. Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation. Drugs 2019; 79(12):1305–1319. doi:10.1007/s40265-019-01159-0.
   PubMed Web of Science ®Google Scholar
• Haemmerle M, Stone R, Menter D, Afshar-Kharghan V, Ak S. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 2018; 33(6):965–983. doi:10.1016/j.ccell.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002;9(3):287–291. doi:10.1007/BF02573067.
   PubMed Web of Science ®Google Scholar